Cellectis SA (CLLS) Shares Sold by Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. decreased its stake in Cellectis SA (NASDAQ:CLLS) by 1.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,101 shares of the company’s stock after selling 234 shares during the period. Oppenheimer & Co. Inc.’s holdings in Cellectis SA were worth $322,000 as of its most recent filing with the SEC.
Several other large investors also recently modified their holdings of the company. Apex Capital Management bought a new stake in shares of Cellectis SA during the first quarter valued at about $254,000. Picton Mahoney Asset Management raised its position in Cellectis SA by 40.7% in the first quarter. Picton Mahoney Asset Management now owns 26,800 shares of the company’s stock worth $737,000 after buying an additional 7,750 shares in the last quarter. Cabot Wealth Management Inc. acquired a new position in Cellectis SA during the second quarter worth $843,000. Landscape Capital Management L.L.C. raised its position in Cellectis SA by 30.0% in the first quarter. Landscape Capital Management L.L.C. now owns 71,500 shares of the company’s stock worth $1,966,000 after buying an additional 16,500 shares in the last quarter. Finally, Taube Hodson Stonex Partners LLP raised its position in Cellectis SA by 58.6% in the second quarter. Taube Hodson Stonex Partners LLP now owns 269,776 shares of the company’s stock worth $7,173,000 after buying an additional 99,664 shares in the last quarter.
Shares of Cellectis SA (NASDAQ:CLLS) traded up 2.31% on Wednesday, reaching $25.23. 47,649 shares of the company’s stock traded hands. Cellectis SA has a 52-week low of $18.00 and a 52-week high of $45.30. The stock’s market cap is $891.40 million. The firm’s 50-day moving average is $26.57 and its 200-day moving average is $27.71.
CLLS has been the subject of a number of recent research reports. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Cellectis SA in a research note on Monday, June 20th. Jefferies Group reiterated a “buy” rating and issued a $47.00 price objective on shares of Cellectis SA in a research note on Friday, September 9th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $44.17.
Cellectis SA Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).
Receive News & Ratings for Cellectis SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis SA and related companies with MarketBeat.com's FREE daily email newsletter.